SLGC SomaLogic, Inc. - Class A
SomaLogic, Inc. discovers, develops, and commercializes life science research tools and clinical diagnostic products for biological and medical science applications. It develops SomaScan, a technology platform that makes protein measurement as DNA measurement, which helps in understanding real-time molecular bases of health and disease that is possible through genomic or other protein technologies. The company also provides SOMAMER REAGENT, a proteomic platform that combines the properties of antibodies and aptamers; SOMAscan assay, a protein biomarker discovery and development tool for protein measurement solutions; and SomaSignal tests that give providers and patients access to the knowledge and insights they need to inform treatment plans and manage health. In addition, it offers diagnostic tests for various diseases and conditions; and protein-measurement assays, kits, and reagents for life science and biopharma researchers; protein biomarker-based diagnostics; and chemical reagents as potential therapeutic molecules. Its products are used in commercial applications, including diagnostic testing, life sciences research tools, therapeutic drugs, and applied markets. The company was incorporated in 1999 and is based in Boulder, Colorado.
$2.39 +0.06 (2.36%)
As of 03/27/2023 14:18:31 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Small cap
GICS sector: Health Care
Industry: Health Information Services
Index country: USA
Country of incorporation: USA
IPO date: 04/23/2021
Outstanding shares: 183,453,347
Average volume: 971,253
Market cap: $410,935,497
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol: BLGYRD4
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%